Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

SOLIDARITY (remdesivir), 2020
 
NCT04315948
RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
2750/2725 inconclusive 18% -3%

COVID 19 all comers meta-analysis

NIH NIAID ACTT-1, 2020
 
NCT04280705
RCTremdesivirplaceboCOVID 19 all comerssome concern
541/521 suggested -40% 26%

COVID-19 mild to moderate meta-analysis

GS-US-540-5774, 10 days, 2020
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
197/200 safety concern -20% 14%
GS-US-540-5774, 5 days, 2020
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
199/200 conclusif -43% demonstrated58%

COVID-19 severe or critically meta-analysis

CAP-China (Wang et al.), 2020
 
NCT04257656
RCTremdesivirplaceboCOVID-19 severe or criticallylow
158/79 inconclusive 9% 21%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).